Literature DB >> 19572122

Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats.

Montserrat Victoriano1, Dominique Hermier, Patrick C Even, Gilles Fromentin, Jean-François Huneau, Daniel Tomé, Renaud de Beaurepaire.   

Abstract

RATIONALE: The antipsychotic drug, olanzapine, often induces weight gain and glucose metabolism disturbances, which may result from feeding pattern abnormalities.
OBJECTIVES: The objectives of the study were to examine the effects of a chronic olanzapine treatment on feeding patterns in the rat and to investigate a potential time-related association between feeding patterns and the appearance of glucose metabolism abnormalities and adiposity.
METHODS: Male rats were treated with olanzapine (2 mg/kg/day), haloperidol (1 mg/kg/day) or a control solution (drugs mixed with the food). In experiment 1, treatments lasted 26 days and feeding patterns were measured on day 21. In experiment 2, treatments lasted for 46 days, and an oral glucose tolerance test (OGTT) was realised on day 31. At the end of both experiments, plasma parameters and body composition were analysed.
RESULTS: In experiment 1, olanzapine-treated animals showed increased meal number, decreased ingestion rate, meal size and inter-meal interval, and no change in total food intake. Plasma glucose, OGTT and body composition were not altered. In experiment 2, after 31 days of treatment, fasting blood glucose was increased and OGTT indicated an insulin resistance. After 46 days of treatment, hyperglycaemia was aggravated (compared to 31 days), and adiposity was increased in olanzapine-treated animals. In both experiments, the haloperidol-treated rats did not differ from the control ones.
CONCLUSION: Chronic olanzapine treatment produces changes in feeding patterns, in a way consistent with an increased incentive drive to eat. As a whole, the results raise the hypothesis that long-term alteration of feeding pattern by olanzapine may predispose to disturbances in the regulation of energy metabolism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19572122     DOI: 10.1007/s00213-009-1593-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  49 in total

1.  Feeding patterns and meal microstructure during development of a taste aversion to a threonine devoid diet.

Authors:  S Feurté; D Tomé; D W Gietzen; P C Even; S Nicolaïdis; G Fromentin
Journal:  Nutr Neurosci       Date:  2002-09       Impact factor: 4.994

Review 2.  Meal frequency and energy balance.

Authors:  F Bellisle; R McDevitt; A M Prentice
Journal:  Br J Nutr       Date:  1997-04       Impact factor: 3.718

3.  The effects of novel antipsychotics on glucose and lipid levels.

Authors:  Donna A Wirshing; Jennifer A Boyd; Laura R Meng; Jacob S Ballon; Stephen R Marder; William C Wirshing
Journal:  J Clin Psychiatry       Date:  2002-10       Impact factor: 4.384

4.  Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection.

Authors:  Julie Minet-Ringuet; Patrick C Even; Benjamin Guesdon; Daniel Tomé; Renaud de Beaurepaire
Journal:  Behav Brain Res       Date:  2005-09-08       Impact factor: 3.332

5.  A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors.

Authors:  James L Roerig; James E Mitchell; Martina de Zwaan; Ross D Crosby; Blake A Gosnell; Kristine J Steffen; Stephen A Wonderlich
Journal:  J Clin Psychopharmacol       Date:  2005-10       Impact factor: 3.153

6.  Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection.

Authors:  Trino Baptista; Emma Araujo de Baptista; Josee Lalonde; Julie Plamondon; N M K Ng Ying Kin; Serge Beaulieu; Rhida Joober; Denis Richard
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-12       Impact factor: 5.067

7.  An animal model of antipsychotic-induced weight gain.

Authors:  Anibal A Arjona; Sandy X Zhang; Brittany Adamson; Richard J Wurtman
Journal:  Behav Brain Res       Date:  2004-06-04       Impact factor: 3.332

8.  A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses.

Authors:  Y C Chagnon; C Mérette; R H Bouchard; C Emond; M-A Roy; M Maziade
Journal:  Mol Psychiatry       Date:  2004-12       Impact factor: 15.992

9.  Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain.

Authors:  G D Cooper; J A Harrold; J C G Halford; A J Goudie
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-09-22       Impact factor: 5.067

10.  The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats.

Authors:  M J Fell; N Anjum; K Dickinson; K M Marshall; L M Peltola; S Vickers; S Cheetham; J C Neill
Journal:  Psychopharmacology (Berl)       Date:  2007-06-21       Impact factor: 4.415

View more
  8 in total

1.  Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters.

Authors:  Kieran J Davey; Siobhain M O'Mahony; Harriet Schellekens; Orla O'Sullivan; John Bienenstock; Paul D Cotter; Timothy G Dinan; John F Cryan
Journal:  Psychopharmacology (Berl)       Date:  2012-01-11       Impact factor: 4.530

2.  Early ethanol and water consumption: accumulating experience differentially regulates drinking pattern and bout parameters in male alcohol preferring (P) vs. Wistar and Sprague Dawley rats.

Authors:  Alexey V Azarov; Donald J Woodward
Journal:  Physiol Behav       Date:  2013-10-02

Review 3.  Atypical antipsychotics and effects on feeding: from mice to men.

Authors:  Louise Benarroch; Chantel Kowalchuk; Virginia Wilson; Celine Teo; Melanie Guenette; Araba Chintoh; Yasika Nesarajah; Valerie Taylor; Peter Selby; Paul Fletcher; Gary J Remington; Margaret K Hahn
Journal:  Psychopharmacology (Berl)       Date:  2016-06-01       Impact factor: 4.530

4.  Subchronic olanzapine treatment decreases the expression of pancreatic glucose transporter 2 in rat pancreatic β cells.

Authors:  Shengqiang Shu; Hao Liu; Min Wang; Dezhen Su; Lihua Yao; Gaohua Wang
Journal:  J Endocrinol Invest       Date:  2014-06-01       Impact factor: 4.256

5.  An evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapine.

Authors:  Claire Wu; Jessica Yuen; Heidi N Boyda; Ric M Procyshyn; Cathy K Wang; Yahya I Asiri; Catherine C Y Pang; William G Honer; Alasdair M Barr
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

6.  Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review.

Authors:  Haiyun Xu; Xiaoyin Zhuang
Journal:  Neuropsychiatr Dis Treat       Date:  2019-07-22       Impact factor: 2.570

7.  Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine.

Authors:  Heidi N Boyda; Ric M Procyshyn; Catherine C Y Pang; Erin Hawkes; Daniel Wong; Chen Helen Jin; William G Honer; Alasdair M Barr
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

8.  Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat.

Authors:  K J Davey; P D Cotter; O O'Sullivan; F Crispie; T G Dinan; J F Cryan; S M O'Mahony
Journal:  Transl Psychiatry       Date:  2013-10-01       Impact factor: 6.222

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.